A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study ...
In trials, a vaccine for pancreatic cancer developed by Sloan-Ketterin and BioNTech showed promise, but researchers say it is ...
The phase 1 trial results, published Feb. 19 in Nature, evaluated the personalized mRNA neoantigen vaccine autogene cevumeran in combination with surgery, immunotherapy drug atezolizumab and ...
Interesting Engineering on MSN9h
New mRNA vaccine shows promise against pancreatic cancer, may extend life by 10 yearsIn a significant development for pancreatic cancer treatment, a phase 1 clinical trial has highlighted the potential of personalized mRNA vaccines to treat the deadly disease. This research comes at a ...
PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit offers insight into the new NCCN guidelines, discusses the new ...
Discover why pancreatic cancer's warning signs often go unnoticed, masquerading as everyday health issues, learn the crucial red flags that shouldn't be ignored ...
A personalized mRNA vaccine may reduce the risks of pancreatic cancer returning after surgery, according to a preliminary ...
There is new hope in the fight against pancreatic cancer after early trials showed that personalized mRNA vaccines can target ...
The tool predicts which of two standard front-line chemotherapy options a patient with advanced pancreatic cancer is likely to benefit from.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback